CC2D1B

Across TCGA pan-cancer cohorts, CC2D1B RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated CC2D1B data layer compared with 3 for mutation status and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CC2D1B RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CC2D1B expression acts as an unfavorable survival marker, although some lineages such as ESCA and CHOL show a favorable association.

LIHC, LGG, and KIRC are the cancer types where CC2D1B RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.426	0.648	<.001	93	view →
LGG	DFS	Median	All	0.613	0.859	<.001	54	view →
KIRC	DFS	Tertile	II,III,IV	0.415	0.601	.005	51	view →
KICH	OS	Tertile	II,III,IV	0.343	1.000	.001	40	view →
CESC	DFS	Tertile	II,III,IV	0.556	0.865	.003	36	view →
MESO	DFS	Quartile	All	0.355	0.786	.006	27	view →
ESCA	DFS	Tertile	II,III,IV	1.000	0.131	.003	24	view →
SARC	OS	Median	All	0.427	0.727	.003	20	view →
LUSC	DFS	Quartile	III,IV	0.306	0.899	.014	16	view →
CHOL	DFS	Quartile	II,III,IV	0.796	0.131	.017	13	view →
UCEC	OS	Quartile	III,IV	0.681	0.424	.036	10	view →
SCLC	DFS	Quartile	III,IV	0.694	0.187	.003	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

CC2D1B–LIHC (DFS)

Open the LIHC breakdown →